Anastrozole or Fulvestrant in Treating Postmenopausal Patients With Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Fulvestrant
Related studies linked through entity extraction aliases.
Study of AVE1642 (IGF-1R/CD221) in Combination With Fulvestrant (Faslodex®) in Postmenopausal Patients With Advanced Hormono-dependent Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor
- Status
- COMPLETED
- Phase
- PHASE2
ZACtima FASlodex Trial in Postmenopausal Advance Breast Cancer Patients Instead of ZACtima FASlodex Trial
- Status
- TERMINATED
- Phase
- PHASE2
A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Sorafenib and Fulvestrant in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Aromatase Inhibitor Therapy
- Status
- TERMINATED
- Phase
- PHASE2
Fulvestrant With or Without Lapatinib and/or Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer That Progressed After Previous Aromatase Inhibitor Therapy
- Status
- UNKNOWN
- Phase
- PHASE3
Retrospective Brazilian Study of Fulvestrant in Advanced Breast Cancer
- Status
- COMPLETED
- Phase
- N/A
Second Line Breast Cancer Trial
- Status
- COMPLETED
- Phase
- PHASE3
Efficacy of Anastrozole and Fulvestrant in Patients With ER Positive, HER2 Negative, Operable Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Fulvestrant in Treating Patients With Recurrent Ovarian Epithelial Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Efficacy and Safety of 500mg of Fulvestrant
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study of Combined Fulvestrant and Everolimus in Advanced/Metastatic Breast Cancer After Aromatase Inhibitor Failure
- Status
- COMPLETED
- Phase
- PHASE2
Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy
- Status
- TERMINATED
- Phase
- PHASE2
Bevacizumab + Endocrine Treatment vs Endocrine Treatment as First Line in Postmenopausal Women
- Status
- COMPLETED
- Phase
- PHASE3
Fulvestrant (Faslodex) + Anastrozole (Arimidex) vs Anastrozole
- Status
- TERMINATED
- Phase
- PHASE3
Phase II Trial of Capecitabine With Fulvestrant for Postmenopausal Women With Hormone Receptor Positive Metastatic Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Fulvestrant in Hormone Refractory Prostate Cancer
- Status
- COMPLETED
- Phase
- PHASE2
AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer.
- Status
- COMPLETED
- Phase
- PHASE2
Enzastaurin Plus Fulvestrant vs. Placebo Plus Fulvestrant in Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2